Page History

...

The example below shows a use-case of undesired, unwanted cellular immune responses toward a protein therapeutic delivered through the viral vector technology. In this case, cellular T-cell responses to both the viral vector and the therapeutic peptide (which is translated from the transgene delivered by the viral vector), are measured before and after study treatment. The T cell responses to both the vector and the theraptucis peptide are considered as "undesired/unwanted", which are indicated by the ISCAT = VECTOR-INDUCED IMMUNOGENICITY, and ISCAT = ANTIDRUG T CELL-MEDIATED IMMUNOGENICITY.Additionally, both anti-drug antibodies (ADA) and anti-drug T cell-mediated immunogenicity are considered as "anti-drug immunogenicity".